Connection

Vito Lampasona to Autoantibodies

Back to Details
This is a "connection" page, showing publications Vito Lampasona has written about Autoantibodies.
Vito Lampasona
Connection Strength
1.302
Autoantibodies
  1. Measurement of Autoantibodies to Gastric H+,K+-ATPase (ATP4A/B) Using a Luciferase Immunoprecipitation System (LIPS). Methods Mol Biol. 2019; 1901:113-131.
    View in: PubMed
    Score: 0.335
  2. No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. Cancer Biomark. 2018; 22(2):351-357.
    View in: PubMed
    Score: 0.312
  3. Autoantibody binding in liquid phase to IL-2 in human sera is not type 1 diabetes specific. Diabetologia. 2017 09; 60(9):1834-1835.
    View in: PubMed
    Score: 0.303
  4. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021 08 19; 6(62).
    View in: PubMed
    Score: 0.100
  5. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020 10 23; 370(6515).
    View in: PubMed
    Score: 0.094
  6. Autoantibodies to N-terminally truncated GAD improve clinical phenotyping of individuals with adult-onset diabetes: Action LADA 12. Diabetologia. 2018 07; 61(7):1644-1649.
    View in: PubMed
    Score: 0.079
  7. A novel LIPS assay for insulin autoantibodies. Acta Diabetol. 2018 Mar; 55(3):263-270.
    View in: PubMed
    Score: 0.078
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.